1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market

Imminent Arrival of 3 Promising Drug Classes Intensifies Competition

Executive Summary

•The market for moderate-to-severe psoriasis therapeutics is becoming increasingly competitive with the imminent arrival of a new class of biologic: anti-interleukin–17(IL-17). If approved, Novartis will lead the pack with a potential 2014 launch of first-in-class secukinumab, followed by Eli Lilly’s izekizumab and Amgen/AstraZeneca’s brodalumab.
•The market also looks to benefit from the arrival of xxnovel oral drugs: Pfizer’s Xeljanz, a janus kinase (JAK) inhibitor approved for rheumatoid arthritis (RA) in the United States, and Celgene’s Apremilast, a phosphodiesterase-4 (PDE4) inhibitor.
•The development pipeline for moderate-to-severe psoriasis therapeutics is competitive, with at leastxx investigational biologic and small molecule drugs in various stages of development. Particularly competitive classes include anti-IL-17 with xx candidates in late stage development and anti-interleukin-23 (IL-23) with 5 candidates in various stages of development.
oThere are also xxbiosimilar anti-tumor necrosis factor (TNF) agents in Phase xx trials for psoriasis— biosimilar versions of adalimumab and 1 biosimilar etanercept.
•The pipeline for mild-to-moderate psoriasis includes at least xxinvestigational topical therapies in various stages of development.
•Pivotal clinical trial programs for 6 late-stage candidates comprise xx to xx trials each and include approximatelyxx to xxpatients in total. Most include at least 1 study design that evaluates the effects of treatment withdrawal and retreatment, which is a common practice with psoriasis patients.
•Comparative head-to-head trials have also become a common practice, with most sponsors of late-stage candidates pitting their drugs against Enbrel (etanercept) or Stelara (ustekimumab) in the case of brodalumab. Novartis was the first to show superiority of an anti-IL-17 over an anti-TNF (Enbrel) in a Phasexx trial with recently announced results of FIXTURE.

Methodology and Scope

•This research service focuses on prescription drugs used for the treatment of mild-to-moderate and moderate-to-severe chronic plaque psoriasis (PS). This study does not cover non-pharmaceutical therapies such as phototherapy or treatments for related disorders such as psoriatic arthritis (PsA).
•A product and pipeline assessment is provided for marketed and investigational products for the treatment of chronic PS. Segmentation by disease severity and drug class is provided, along with additional supporting information such as clinical trial timelines and results, projected launch timelines, and epidemiology.
•The information contained in this research service was derived from published sources, including the following: disease organization Web sites; public health organization Web sites; company publications, including annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.

Introduction

Psoriasis is a chronic inflammatory disease of varying severity that manifests primarily as inflammation of the skin in the form of scaling, erythematous, disfiguring plaques that may be associated with pain, itching, and significant quality of life issues. Despite localization of the main symptom to the skin, psoriasis is a systemic autoimmune inflammatory disease. It is often associated with co-morbidities such as PsA, inflammatory bowel diseases, cardiovascular disease, diabetes, and lymphoma; severe cases may increase overall mortality risk. There is currently no cure for psoriasis. The goal of treatment is to reduce the severity and coverage of lesions and to induce and maintain remission for as long as possible.

The market for psoriasis treatments is mainly focused on developing improved therapeutic options for moderate-to-severe cases of psoriasis where there is still a great deal of unmet need. Since the introduction of biologic therapies such as TNF inhibitors for psoriasis and related autoimmune diseases such as RA, treatment of these diseases has greatly improved because of the strong efficacy of these revolutionary therapies. However, available biologics are associated with varying or waning efficacy, along with significant safety issues such as infections.

Table Of Contents

Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market
Executive Summary
Methodology and Scope
Introduction
Market Background
Disease Classification
Epidemiology
Efficacy Assessment Tools
Segmentation
Psoriasis Therapeutics Market
Competitive Landscape—Mild-to-moderate PS, Products in Development
Competitive Landscape—Moderate-to-severe PS, Marketed Products and Products in Development
Competitive Landscape—Pivotal Phase 3 Trials
Timeline of Key Events
Comparative Efficacy of Select Marketed and Investigational Drugs
Comparative Efficacy Discussion
Marketed Products Analysis
Pipeline Analysis
Product Dashboards
Conclusions and Recommendations
New Market Opportunities
Companies to Watch
Legal Disclaimer
Appendix
Comparative Efficacy of Select Marketed and Investigational Drugs
The Frost and Sullivan Story

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based ...

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Pathology Statistics in France

  • November 2016
    2 pages
  • Pathology  

  • France  

    Europe  

    United States  

View report >

Influenza Statistics in the US

  • November 2016
    7 pages
  • Influenza  

    Influenza Vacci...  

    Vaccine  

  • United States  

View report >

Related Market Segments :

Autoimmune Disease
Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.